Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Alnylam Pharmaceuticals Inc., 3 years.
Alnylam Pharmaceuticals Inc.
Director
Myriad Genetics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +18,000 | $100.65 | $1,811,700 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,645 | $457.44 | $752,489 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,888 | $458.86 | $866,328 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,403 | $459.73 | $645,001 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −473 | $460.71 | $217,916 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −2,290 | $461.92 | $1,057,797 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,652 | $463.00 | $764,876 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −799 | $464.36 | $371,024 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −222 | $471.25 | $104,618 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −823 | $472.82 | $389,131 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −838 | $474.22 | $397,396 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −951 | $474.85 | $451,582 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −972 | $476.31 | $462,973 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,183 | $477.47 | $564,847 |
| Sep 9, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,450 | $478.67 | $694,072 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.